Leerink Partners Resumes Nabriva Therapeutics AG (NBRV) at Outperform

October 27, 2016 7:45 AM EDT
Get Alerts NBRV Hot Sheet
Price: $4.06 -2.64%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade NBRV Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Leerink Partners resumes coverage on Nabriva Therapeutics AG (NASDAQ: NBRV) with a Outperform rating and a price target of $14.00.

Analyst Paul Matteis commented, "We continue to believe Nabriva is unique among its late stage antibiotic peers as it advances an IV-to-oral, novel mechanism of action product through late stage clinical trial in community acquired bacterial pneumonia (CAP). Lefamulin is a "pleuromutilin," a novel anti-infective which previously showed comparable efficacy to vancomycin in a phase 2 study in skin infections. While the uniqueness – and therefore lack of widespread experience with the drug/class in humans - implies higher than average risk to Phase 3, Lefamulin's differentiated profile may also offer greater reward upon study success. Specifically, feedback from MEDACorp KOLs and payors suggest the potential for faster uptake given (1) physician confidence in the lack of pre-existing bacterial resistance and (2) relatively easier reimbursement given the lack of generic comps in the same class."

For an analyst ratings summary and ratings history on Nabriva Therapeutics AG click here. For more ratings news on Nabriva Therapeutics AG click here.

Shares of Nabriva Therapeutics AG closed at $5.91 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Add Your Comment